Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05862012 · ClinicalTrials.gov registry record · Phase 1
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
A Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by Ichnos Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 11
- Study locations
NCT05862012: Recruiting Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by Ichnos Sciences.
NCT05862012 is a Phase 1 study of Relapsed/Refractory Multiple Myeloma that is actively recruiting participants, run by Ichnos Sciences. The registered enrollment target is 200 participants, above the 158-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (27% higher). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05862012, a Phase 1 study of Relapsed/Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Ichnos Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).
Conditions Studied
Interventions
- DRUG ISB 2001
Study Locations (11)
Victoria
- St. Vincent's Hospital Melbourne - Fitzroy
- Peter MacCallum Cancer Center - Melbourne
California
- Standford Cancer Institute - Palo Alto
Illinois
- University of Chicago Medical Center - Chicago
New York
- Montefiore Medical Center - The Bronx
North Carolina
- University of North Carolina - Chapel Hill
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
New South Wales
- Concord Hospital - Concord
Queensland
- Pindara Private Hospital - Benowa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
What NCT05862012 shows while recruiting
NCT05862012 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 158-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (27% higher).
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which ISB 2001 is the first listed.
NCT05862012 lists 11 locations in 10 states (Victoria, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT05862012 about?
NCT05862012 is a clinical study titled "Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)". This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).
What is the current status of trial NCT05862012?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2023-11-01. Estimated completion is 2027-07.
What conditions does trial NCT05862012 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05862012?
The interventions under investigation include: ISB 2001 (DRUG).
Who is sponsoring clinical trial NCT05862012?
This trial is sponsored by Ichnos Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05862012 being conducted?
This trial has 11 study locations across California, Illinois, New York, North Carolina, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05862012's enrollment target sits among peer trials
200 6th of 14 higher than 9 of 14 other Relapsed/Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed/Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI